Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM1M57I)

Drug Name
MK-2578 Drug Info
Indication
Disease Entry ICD 11 Status REF
Anemia 3A00-3A9Z Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM1M57I

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Erythropoietin (EPO) TTQG4NR EPO_HUMAN Agonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Erythropoietin (EPO) DTT EPO 4.717 3.225 1 3.781
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Anemia
ICD Disease Classification 3A00-3A9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Erythropoietin (EPO) DTT EPO 5.72E-01 -0.15 -0.83
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00968617) A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002). U.S. National Institutes of Health.
2 Merck ditches biogeneric. Nat Biotechnol. 2010 Jul;28(7):636.